JP2013522302A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522302A5
JP2013522302A5 JP2013500127A JP2013500127A JP2013522302A5 JP 2013522302 A5 JP2013522302 A5 JP 2013522302A5 JP 2013500127 A JP2013500127 A JP 2013500127A JP 2013500127 A JP2013500127 A JP 2013500127A JP 2013522302 A5 JP2013522302 A5 JP 2013522302A5
Authority
JP
Japan
Prior art keywords
yeast
immunotherapy composition
interferon
based immunotherapy
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013500127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522302A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028359 external-priority patent/WO2011115914A1/en
Publication of JP2013522302A publication Critical patent/JP2013522302A/ja
Publication of JP2013522302A5 publication Critical patent/JP2013522302A5/ja
Withdrawn legal-status Critical Current

Links

JP2013500127A 2010-03-14 2011-03-14 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 Withdrawn JP2013522302A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US31377510P 2010-03-14 2010-03-14
US31377410P 2010-03-14 2010-03-14
US31377610P 2010-03-14 2010-03-14
US61/313,774 2010-03-14
US61/313,775 2010-03-14
US61/313,776 2010-03-14
US37089910P 2010-08-05 2010-08-05
US61/370,899 2010-08-05
US40785910P 2010-10-28 2010-10-28
US61/407,859 2010-10-28
PCT/US2011/028359 WO2011115914A1 (en) 2010-03-14 2011-03-14 Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy

Publications (2)

Publication Number Publication Date
JP2013522302A JP2013522302A (ja) 2013-06-13
JP2013522302A5 true JP2013522302A5 (enExample) 2014-05-01

Family

ID=44649537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500127A Withdrawn JP2013522302A (ja) 2010-03-14 2011-03-14 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療

Country Status (4)

Country Link
US (1) US20130121964A1 (enExample)
EP (1) EP2547792A4 (enExample)
JP (1) JP2013522302A (enExample)
WO (1) WO2011115914A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687030B (zh) 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
WO2008115610A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
US20120196272A1 (en) * 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US20140011769A1 (en) * 2012-07-03 2014-01-09 Chimerix, Inc. Methods of Treating Retroviral Infections and Related Dosage Regimes
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
CA2948803A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
EP3234181A1 (en) * 2014-12-18 2017-10-25 F. Hoffmann-La Roche AG Biomarkers for hbv treatment response
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
WO2016159178A1 (ja) * 2015-03-30 2016-10-06 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2017009303A1 (en) * 2015-07-15 2017-01-19 F. Hoffmann-La Roche Ag Biomarkers for hbv treatment response
TWI748957B (zh) 2015-08-03 2021-12-11 美商環球免疫公司 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物
RU2623151C2 (ru) * 2015-11-03 2017-06-22 Федеральное государственное казенное учреждение Главный клинический военный госпиталь ФСБ России Способ прогнозирования динамики фиброза печени у пациентов с хроническим гепатитом С, генотипом 1, не ответивших на лечение пегилированными интерферонами и рибавирином
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
JP7417339B1 (ja) 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR20070068460A (ko) * 2004-10-18 2007-06-29 글로브이뮨 만성 ｃ형 간염에 대한 효모계 치료
WO2007008780A2 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
AU2010249379B2 (en) * 2009-05-21 2013-09-26 Merck Sharp & Dohme Corp. Genetic markers associated with interferon-alpha response
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition

Similar Documents

Publication Publication Date Title
JP6668468B2 (ja) Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
Sherman et al. Entecavir therapy for lamivudine‐refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks
JP2012513479A5 (enExample)
Brunetto et al. Interferon therapy of chronic hepatitis B
JP2016531144A5 (enExample)
JP2018531272A6 (ja) Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
JP2012519181A5 (enExample)
JP2015517528A5 (enExample)
JP2012503011A5 (ja) 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物
RU2015114543A (ru) Способы лечения гепатита с
Mallet et al. The impact of human immunodeficiency virus on viral hepatitis
JP2014504643A5 (enExample)
JP2015528449A5 (enExample)
JP2013529627A5 (enExample)
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
JP2019505553A5 (enExample)
RU2015114566A (ru) Способы лечения гепатита с
CN102083435A (zh) 特拉匹韦给药方案
Marcellin et al. CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS: 476
Takkenberg et al. New developments in antiviral therapy for chronic hepatitis B
Chen et al. The current status of combination therapy of chronic hepatitis B.
Mahtab et al. REP 9AC': A second generation HBsAg release inhibitor with improved tolerability: 424
Sokal et al. Chapter 6.1. Pediatric chronic hepatitis B and C: 30 years of ESPGHAN clinical research and recommendations
Papatheodoridis et al. CHANGES OF SERUM HBSAG LEVELS IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS UNDER LONGTERM THERAPY WITH NUCLEOS (T) IDE ANALOGUE (S): 1458
Lai et al. Management of chronic hepatitis B